{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:02Z","timestamp":1770287702439,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ecl.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T16:30:36Z","timestamp":1403886636000},"page":"769-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Osteoporosis and Fracture Risk Associated with HIV Infection and Treatment"],"prefix":"10.1016","volume":"43","author":[{"given":"Juliet","family":"Compston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2014.05.001_bib1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/gerona\/glt093","article-title":"Public health impact of osteoporosis","volume":"68","author":"Cauley","year":"2013","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ecl.2014.05.001_bib2","series-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series","author":"World Health Organization","year":"1994"},{"key":"10.1016\/j.ecl.2014.05.001_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.ecl.2014.05.001_bib4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2014.05.001_bib5","series-title":"Assessment of osteoporosis at the primary healthcare level. Technical Report","author":"Kanis","year":"2008"},{"key":"10.1016\/j.ecl.2014.05.001_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00002030-200104130-00005","article-title":"Osteopenia in HIV-infected men: association with asymptomatic lactic acidaemia and lower weight pre-antiretroviral therapy","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200104130-00022","article-title":"Osteopenia in HIV-infected patients: is it the disease or is it the treatment?","volume":"15","author":"Knobel","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib8","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200309050-00010","article-title":"Decreased bone mineral density in HIV-infected patients is independent of retroviral therapy","volume":"17","author":"Bruera","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib9","first-page":"221","article-title":"Osteopenia in HIV-infected women prior to highly active antiretroviral therapy","volume":"46","author":"Teichmann","year":"2003","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.ecl.2014.05.001_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002030-200402200-00014","article-title":"Reduced bone density in HIV-infected women","volume":"18","author":"Dolan","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1359\/JBMR.0301246","article-title":"BMD is reduced in HIV-infected men irrespective of treatment","volume":"19","author":"Amiel","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2014.05.001_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00198-005-1845-0","article-title":"Bone mass and mineral metabolism in HIV+ postmenopausal women","volume":"16","author":"Yin","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2014.05.001_bib13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/501015","article-title":"HIV and bone mineral density in middle-aged women","volume":"42","author":"Arnsten","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11908-006-0012-x","article-title":"Osteopenia and osteoporosis in patients with HIV: a review of current concepts","volume":"8","author":"Brown","year":"2006","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ecl.2014.05.001_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/498511","article-title":"Bone disease and HIV infection","volume":"42","author":"Amorosa","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0b013e3280148c05","article-title":"Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection","volume":"21","author":"Arnsten","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/cid\/cis455","article-title":"Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B","volume":"55","author":"Mulligan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib19","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/00002030-200107060-00009","article-title":"Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir","volume":"15","author":"Nolan","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1310\/4X0H-UVMJ-BHYW-CPFB","article-title":"Relationship between low bone mineral density and highly active retroviral therapy including protease inhibitors in HIV-infected patients","volume":"4","author":"Fernandez-Rivera","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ecl.2014.05.001_bib21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","article-title":"Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals","volume":"36","author":"Mondy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2265.2006.02572.x","article-title":"Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active retroviral therapy","volume":"65","author":"Bolland","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2014.05.001_bib23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archinte.166.11.1225","article-title":"Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial","volume":"166","author":"Dolan","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2014.05.001_bib24","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1210\/jc.2006-0127","article-title":"Longitudinal analysis of bone density in human immunodeficiency-infected women","volume":"91","author":"Dolan","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2265.2007.02875.x","article-title":"Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years","volume":"67","author":"Bolland","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2014.05.001_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/QAI.0b013e3181bf6471","article-title":"Short-term bone loss in HIV-infected premenopausal women","volume":"53","author":"Yin","year":"2010","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ecl.2014.05.001_bib27","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1210\/jc.2011-0591","article-title":"Stable bone density in HAART-treated individuals with HIV: a meta-analysis","volume":"96","author":"Bolland","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1210\/jc.2011-2197","article-title":"Higher rates of bone loss in post-menopausal HIV-infected women: a longitudinal study","volume":"97","author":"Yin","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib29","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1210\/jc.2007-1660","article-title":"Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis","volume":"92","author":"Bolland","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-na\u00efve HIV-1-infected patients","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ecl.2014.05.001_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen","volume":"51","author":"Brown","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ecl.2014.05.001_bib32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","article-title":"Continuous antiretroviral therapy decreases bone mineral density","volume":"23","author":"Grund","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib35","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"McComsey","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib36","doi-asserted-by":"crossref","first-page":"e38377","DOI":"10.1371\/journal.pone.0038377","article-title":"Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine","volume":"7","author":"Haskelberg","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ecl.2014.05.001_bib37","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/QAD.0b013e32836378c3","article-title":"Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia","volume":"27","author":"Assoumou","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib38","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1097\/01.aids.0000432534.47217.b4","article-title":"Bone mineral density in HIV participants randomized to raltegravir and lopinavir\/ritonavir compared with standard second line therapy","volume":"27","author":"Martin","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ecl.2014.05.001_bib40","doi-asserted-by":"crossref","first-page":"e18168","DOI":"10.1371\/journal.pone.0018168","article-title":"Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo\/JngJ Mice","volume":"6","author":"Won","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ecl.2014.05.001_bib41","first-page":"359242","article-title":"Osteoimmunopathology in HIV\/AIDS: a translational evidence-based perspective","volume":"2011","author":"Barkhordarian","year":"2011","journal-title":"Patholog Res Int"},{"key":"10.1016\/j.ecl.2014.05.001_bib42","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00198-012-2189-1","article-title":"Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women","volume":"24","author":"Calmy","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2014.05.001_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00223-013-9716-8","article-title":"Trabecular and cortical microarchitecture in postmenopausal HIV-infected women","volume":"92","author":"Yin","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ecl.2014.05.001_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/QAD.0000000000000070","article-title":"Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life","volume":"28","author":"Yin","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib45","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","article-title":"Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system","volume":"93","author":"Triant","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib46","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1097\/QAD.0b013e32833f6294","article-title":"Fracture incidence in HIV-infected women: results from the Women\u2019s Interagency HIV Study","volume":"24","author":"Yin","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib47","doi-asserted-by":"crossref","first-page":"e17217","DOI":"10.1371\/journal.pone.0017217","article-title":"Increased risk of fragility fractures among HIV infected compared to uninfected male veterans","volume":"6","author":"Womack","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ecl.2014.05.001_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/cid\/ciq242","article-title":"Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000\u20132006","volume":"52","author":"Young","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAD.0b013e32834ed8a7","article-title":"Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study","volume":"26","author":"Hansen","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib50","first-page":"1843","article-title":"HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study","volume":"24","author":"G\u00fcerri-Fernandez","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2014.05.001_bib51","first-page":"1259","article-title":"HIV Infection and its association with an excess risk of clinical fractures: a nationwide case-control study","volume":"28","author":"Prieto-Alhambra","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2014.05.001_bib52","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1097\/QAD.0b013e328361d241","article-title":"Incident fractures in HIV-infected individuals: a systematic review and meta-analysis","volume":"27","author":"Shiau","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAI.0b013e31821ecf4c","article-title":"Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients","volume":"57","author":"Yong","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ecl.2014.05.001_bib54","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1210\/jc.2013-2194","article-title":"Comparative risk of fracture in men and women with HIV","volume":"99","author":"Gedmintas","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib56","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cir626","article-title":"Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study","volume":"53","author":"Hasse","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ecl.2014.05.001_bib57","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1097\/QAD.0b013e328359a8ca","article-title":"Fractures after antiretroviral initiation","volume":"26","author":"Yin","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib58","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.25866","article-title":"Risk of hip fracture associated with hepatitis C virus infection and hepatitis C\/human immunodeficiency virus coinfection","volume":"56","author":"Lo Re","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ecl.2014.05.001_bib59","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/jbmr.1988","article-title":"Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients","volume":"28","author":"Maalouf","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2014.05.001_bib60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/8756-3282(94)00028-X","article-title":"Bone remodeling in human immunodeficiency virus-1-infected patients. A histomorphometric study","volume":"16","author":"Serrano","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2014.05.001_bib61","unstructured":"Brown TT, Fredrick L, Warren D, et\u00a0al. Decreased total bone mineral density in treatment-naive subjects taking lopinavir\/ritonavir combined with raltegravir or tenofovir\/emtricitabine. In: 14th European AIDS Conference. Brussels, 2013."},{"key":"10.1016\/j.ecl.2014.05.001_bib62","unstructured":"European AIDS Clinical Society Guidelines 2013. Available at: http:\/\/eacsociety.org\/Guidelines.aspx. Accessed May 10, 2014."},{"key":"10.1016\/j.ecl.2014.05.001_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrrheum.2009.260","article-title":"Osteoporosis: impact on health and economics","volume":"6","author":"Harvey","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ecl.2014.05.001_bib64","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.ecl.2014.05.001_bib65","article-title":"Interventions for the treatment of decreased bone mineral density associated with HIV infection","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ecl.2014.05.001_bib66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/MD8V-5DLG-EN3T-BRHX","article-title":"Alendronate reduces bone resorption in HIV-associated osteopenia\/osteoporosis","volume":"5","author":"Gueraldi","year":"2004","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ecl.2014.05.001_bib67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","article-title":"Alendronate, vitamin D and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection","volume":"38","author":"Mondy","year":"2005","journal-title":"J\u00a0Acquired Immune Defic Syndr"},{"key":"10.1016\/j.ecl.2014.05.001_bib68","first-page":"343","article-title":"Reversal of HIV-1-associated osteoporosis with once weekly alendronate","volume":"19","author":"Negredo","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib69","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/QAD.0b013e3282ef961d","article-title":"Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV","volume":"21","author":"McComsey","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib70","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2011.0224","article-title":"Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)","volume":"28","author":"Rozenberg","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ecl.2014.05.001_bib71","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/jc.2006-2216","article-title":"Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial","volume":"92","author":"Bolland","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib72","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1210\/jc.2012-1424","article-title":"Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men","volume":"97","author":"Bolland","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2014.05.001_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAD.0b013e32831c8adc","article-title":"A\u00a0double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis","volume":"23","author":"Huang","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ecl.2014.05.001_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2014.05.001_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/rheumatology\/ket236","article-title":"Safety issues with bisphosphonate therapy for osteoporosis","volume":"53","author":"Suresh","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.ecl.2014.05.001_bib76","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","article-title":"Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw","volume":"22","author":"Compston","year":"2011","journal-title":"Osteoporos Int"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852914000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852914000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:39:16Z","timestamp":1760175556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852914000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0889852914000395"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2014.05.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis and Fracture Risk Associated with HIV Infection and Treatment","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}